Citation
Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of death with SGLT2 inhibitors in observational studies: Real or bias? Diabetes Care. 2018;41(6):e106-e8.
Abstract
Two recent observational studies reported a remarkably lower rate of all-cause death associated with sodium-glucose cotransporter 2 inhibitor (-SGLT2i) use in all patients with type 2 diabetes and not only those at increased cardiovascular risk. The >50% lower mortality rates reported in these studies are much greater than those found in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and CANagliflozin cardioVascular Assessment Study (CANVAS) randomized trials.